Published in Gene Therapy Weekly, August 29th, 2002
This patent covers methods for producing AAV vectors in large amounts or high titers.
"Avigen continues to make progress in optimizing efficient, high-yield production and purification methods for AAV vector manufacturing to support the commercialization of AAV-based gene therapy products," said John Monahan, PhD, Avigen's president and CEO.
"This patent covers the utilization of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.